[go: up one dir, main page]

EE200000152A - Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon - Google Patents

Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon

Info

Publication number
EE200000152A
EE200000152A EEP200000152A EEP200000152A EE200000152A EE 200000152 A EE200000152 A EE 200000152A EE P200000152 A EEP200000152 A EE P200000152A EE P200000152 A EEP200000152 A EE P200000152A EE 200000152 A EE200000152 A EE 200000152A
Authority
EE
Estonia
Prior art keywords
mcp
amino
pharmaceutical composition
host cell
expression vector
Prior art date
Application number
EEP200000152A
Other languages
English (en)
Inventor
Proost Paul
Struyf Sofie
Van Damme Jo
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200000152(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200000152A publication Critical patent/EE200000152A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EEP200000152A 1997-09-29 1998-09-28 Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon EE200000152A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97116863A EP0906954A1 (en) 1997-09-29 1997-09-29 Amino-terminal truncated c-c chemokines as chemokine antagonist
EP97122471A EP0905240A1 (en) 1997-09-29 1997-12-19 Amino-terminally truncated c-c chemokines as chemokine antagonists
EP98104216A EP0905241A1 (en) 1997-09-29 1998-03-10 Amino-terminally truncated c-c chemokines as chemokine antagonists
PCT/EP1998/006142 WO1999016876A1 (en) 1997-09-29 1998-09-28 Amino-terminally truncated mcp-2 as chemokine antagonists

Publications (1)

Publication Number Publication Date
EE200000152A true EE200000152A (et) 2001-02-15

Family

ID=8227408

Family Applications (2)

Application Number Title Priority Date Filing Date
EEP200000151A EE200000151A (et) 1997-09-29 1998-09-28 Aminoterminaalselt kärbitud rantes vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
EEP200000152A EE200000152A (et) 1997-09-29 1998-09-28 Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EEP200000151A EE200000151A (et) 1997-09-29 1998-09-28 Aminoterminaalselt kärbitud rantes vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon

Country Status (28)

Country Link
US (5) US6977071B2 (et)
EP (6) EP0906954A1 (et)
JP (2) JP4230659B2 (et)
KR (2) KR100560275B1 (et)
CN (3) CN1145693C (et)
AR (2) AR013528A1 (et)
AT (3) ATE368742T1 (et)
AU (2) AU750341B2 (et)
BG (2) BG64679B1 (et)
BR (2) BR9812565A (et)
CA (2) CA2304827A1 (et)
CY (1) CY1110927T1 (et)
CZ (2) CZ299478B6 (et)
DE (3) DE69823218T2 (et)
DK (3) DK1021541T3 (et)
EA (2) EA003940B1 (et)
EE (2) EE200000151A (et)
ES (3) ES2218860T3 (et)
HU (2) HU226414B1 (et)
IL (2) IL135352A (et)
NO (2) NO20001584D0 (et)
NZ (3) NZ503234A (et)
PL (2) PL197569B1 (et)
PT (3) PT1439231E (et)
SK (2) SK286439B6 (et)
UA (2) UA73081C2 (et)
WO (2) WO1999016876A1 (et)
ZA (2) ZA988676B (et)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
AU1616499A (en) 1997-12-01 1999-06-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chemokine variants and methods of use
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
ATE339504T1 (de) * 1999-10-25 2006-10-15 Pharis Biotec Gmbh Prozessiertes menschliches chemokin phc-1
EP1167527A1 (en) * 2000-06-22 2002-01-02 Euroscreen S.A. Processed human chemokines PHC-1 and PHC-2
AU2505601A (en) * 1999-11-15 2001-05-30 Wolf-Georg Forssmann Novel use of hcc-2
CA2316405A1 (en) * 2000-05-26 2001-11-26 Ian Clark-Lewis Modulation of inflammation by protease products
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
GB2373785A (en) * 2001-03-28 2002-10-02 Rega Inst For Medical Res Truncating chemokines using dipeptidyl peptidase IV
WO2003051921A1 (en) 2001-12-17 2003-06-26 Applied Research Systems Ars Holding N.V. Chemokine mutants acting as chemokine antagonists
WO2004104216A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
DE102005049637A1 (de) * 2005-10-14 2007-04-26 Rheinisch-Westfälische Technische Hochschule Aachen Antagonisten gegen die Interaktion von PF4 und RANTES
JP5624884B2 (ja) 2007-08-02 2014-11-12 ノビミューンエスアー 抗ｒａｎｔｅｓ抗体およびその使用の方法
WO2011097567A1 (en) * 2010-02-08 2011-08-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Rantes multiplexed assay, rantes variants related to disease, and rantes variants related to enzymatice activity
EP2545174B1 (en) 2010-03-11 2015-11-11 Health Research, Inc. Methods and compositions containing fc fusion proteins for enhancing immune responses
TW201718851A (zh) * 2015-09-18 2017-06-01 通用醫院公司 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
WO2019229615A1 (en) 2018-05-28 2019-12-05 Université De Genève Methods of inhibiting cerebral inflammation
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0311107A3 (en) 1987-10-08 1990-04-18 Stichting REGA V.Z.W. Anti-hiv active 3'-fluoro-purine-2',3'-dideoxyribosides
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
HU221089B1 (en) * 1994-12-08 2002-08-28 Glaxo Group Ltd Rantes peptide derivates with antagonistic effect and uses thereof
WO1997025427A1 (en) * 1996-01-12 1997-07-17 Genetics Institute, Inc. Beta-chemokine, h1305 (mcp-2)
JP2000508527A (ja) * 1996-03-27 2000-07-11 アイコス コーポレイション 単球走化性タンパク質―５物質及び方法
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use

Also Published As

Publication number Publication date
ATE263242T1 (de) 2004-04-15
PT1021541E (pt) 2004-07-30
CN1148447C (zh) 2004-05-05
CN1145693C (zh) 2004-04-14
CN1271386A (zh) 2000-10-25
US20050201977A1 (en) 2005-09-15
CZ20001146A3 (cs) 2000-09-13
DK1439231T3 (da) 2007-11-05
EA003942B1 (ru) 2003-10-30
BG104266A (en) 2000-11-30
KR20010024214A (ko) 2001-03-26
SK4512000A3 (en) 2000-09-12
HU226414B1 (en) 2008-11-28
EP1021541A1 (en) 2000-07-26
HU226468B1 (en) 2008-12-29
HUP0003505A3 (en) 2005-11-28
HK1032426A1 (en) 2001-07-20
JP4230659B2 (ja) 2009-02-25
BG64679B1 (bg) 2005-11-30
CN1271385A (zh) 2000-10-25
EP0905241A1 (en) 1999-03-31
US20050164936A1 (en) 2005-07-28
EP0906954A1 (en) 1999-04-07
ATE264390T1 (de) 2004-04-15
EP1439231B1 (en) 2007-08-01
SK4502000A3 (en) 2000-09-12
PL339545A1 (en) 2000-12-18
HK1062637A1 (en) 2004-11-19
EP1439231A3 (en) 2004-12-22
AR013529A1 (es) 2000-12-27
AU750341B2 (en) 2002-07-18
DE69823218D1 (de) 2004-05-19
HK1032425A1 (en) 2001-07-20
US6977071B2 (en) 2005-12-20
US7326411B2 (en) 2008-02-05
BG64757B1 (bg) 2006-02-28
CZ299479B6 (cs) 2008-08-06
WO1999016877A1 (en) 1999-04-08
EP1439231A2 (en) 2004-07-21
NO20001609L (no) 2000-03-28
CA2304827A1 (en) 1999-04-08
AU750606B2 (en) 2002-07-25
UA73080C2 (en) 2005-06-15
BG104267A (en) 2000-11-30
US20050220790A1 (en) 2005-10-06
US20030124677A1 (en) 2003-07-03
DE69822856T2 (de) 2004-08-19
HUP0003563A2 (hu) 2001-02-28
DE69838188D1 (de) 2007-09-13
DE69823218T2 (de) 2004-08-26
US6905676B2 (en) 2005-06-14
BR9812565A (pt) 2000-08-01
JP4233214B2 (ja) 2009-03-04
US7338653B2 (en) 2008-03-04
ES2215324T3 (es) 2004-10-01
HUP0003563A3 (en) 2005-11-28
KR20010024213A (ko) 2001-03-26
US20030119148A1 (en) 2003-06-26
EP0905240A1 (en) 1999-03-31
DE69838188T2 (de) 2007-11-22
KR100560275B1 (ko) 2006-03-10
PL197569B1 (pl) 2008-04-30
DK1019507T3 (da) 2004-07-19
EA200000379A1 (ru) 2000-10-30
WO1999016876A1 (en) 1999-04-08
CZ20001147A3 (cs) 2000-09-13
PT1439231E (pt) 2007-08-20
NO20001584L (no) 2000-03-27
ES2218860T3 (es) 2004-11-16
JP2001518297A (ja) 2001-10-16
AR013528A1 (es) 2000-12-27
NO20001584D0 (no) 2000-03-27
CZ299478B6 (cs) 2008-08-06
ES2287601T3 (es) 2007-12-16
HUP0003505A2 (hu) 2001-02-28
NZ503235A (en) 2002-08-28
DK1021541T3 (da) 2004-08-02
ZA988675B (en) 1999-11-24
CA2305017A1 (en) 1999-04-08
UA73081C2 (en) 2005-06-15
NZ503234A (en) 2002-06-28
NO20001609D0 (no) 2000-03-28
PL339559A1 (en) 2000-12-18
EP1019507A1 (en) 2000-07-19
SK286495B6 (sk) 2008-11-06
ZA988676B (en) 1999-12-03
IL135352A (en) 2006-08-20
CY1110927T1 (el) 2015-06-10
CN1490049A (zh) 2004-04-21
EE200000151A (et) 2001-02-15
JP2001518296A (ja) 2001-10-16
EP1021541B1 (en) 2004-04-14
IL135351A (en) 2006-08-20
AU9747498A (en) 1999-04-23
CN1233415C (zh) 2005-12-28
AU9442098A (en) 1999-04-23
PT1019507E (pt) 2004-06-30
EP1019507B1 (en) 2004-03-31
PL196427B1 (pl) 2008-01-31
BR9812394A (pt) 2000-09-12
EA003940B1 (ru) 2003-10-30
SK286439B6 (sk) 2008-10-07
EA200000378A1 (ru) 2000-10-30
NZ516027A (en) 2003-05-30
ATE368742T1 (de) 2007-08-15
KR100542934B1 (ko) 2006-01-11
DE69822856D1 (de) 2004-05-06

Similar Documents

Publication Publication Date Title
EE200000152A (et) Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
BR9610511B1 (pt) construções de dna, úteis em terapia genética, compreendendo ao menos uma sequência nucléica de interesse e composição farmacêutica.
ATE315087T1 (de) Neuartige auf p53 ansprechende gene
BR9507678A (pt) Construção de dna vetor de expressão recombinante célula proceso para produzir uma enzima enzima preparação de enzima uso da enzima e cultura
DE69824597D1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
BR9607273A (pt) Molécula de dna duplo filamento dna recombinante plasmídio célula recombinante composiçao farmacéutica e processo de preparaçao de uma molécula de dna
EP0760849A4 (en) RECOMBINANT BACTERICIDAL PERMEABILITY (BPI) AND LIPOSACCHARIDE (LBD) RECOMBINANT PROTEINS, MOLECULES ENCODING THE SAME, THEIR PRODUCTION METHODS AND THEIR USES
EE200000355A (et) IFN/IFNAR kompleks ja vastav molekul ning nende kasutamine, DNA, peremeesrakk, liitvalgu valmistamismeetod, I tüüpi IFN säilimisaja pikendamise meetod, farmatseutiline kompositsioon ja IFNAR kasutamine
FI973309A0 (fi) Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi
ATE419358T1 (de) Gebrauchsverfaheren eines neuen lysyloxidase- verwandten proteins
ATE310085T1 (de) Cyclin-e2 proteine und dafür kodierende gene
WO2004005475A3 (en) Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
FI971100L (fi) Menetelmä yhdistelmä-DNA-proteiinien, plasmidien ja modifioitujen solujen tuottamiseksi
DE69737766D1 (de) Zusammensetzungen von stammzellfaktor (scf)-analogen und auf diese bezogene verfahren
DE59712554D1 (de) Rekombinante expression von s-layer-proteinen
CA2032167A1 (en) Dna coding for protein binds to enhancer of.alpha.-fetoprotein gene
MD20000034A (ro) Proteinele virusului răsucirii frunzelor de viţă de vie (tipul 2) şi utilizarea lor
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
ATE435277T1 (de) 18477, eine menschliche proteinkinase und deren verwendung
ATE346919T1 (de) Nebenhoden-spezifisches rezeptorprotein und dessen verwendung
DE69329164D1 (de) Protein mit Alpha-Glukosidase-Aktivität, DNS mit dessen genetischer Information und Herstellung von Alpha-Glukosidase
DE3584029D1 (de) Expressionsvektoren, dns-fragmente, peptide, wirte und verfahren zur herstellung von peptiden.
EP0676413A3 (en) Interferon alpha / beta binding protein, its production and application.
BR9606521A (pt) Polinucleotídeo purificado e isolado molécula de dna construção de expressão de dna célula hospedeira método para produzir um polipeptídeo humano polipeptídeo purificado e isolado anticorpo e linhagem celular de hibridoma
BR9508430A (pt) Sequência nucleotídica ADN recombinante vetor de expressão com replicação autônoma e/ou integrativo célula recombinante polipeptideo processo de produção de um polipeptideo topoismorase isolada e utilização de uma topoisomeras IV

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner